A Phase 3 interventional study of Atorvastatin and Simvastatin in Familial Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the efficacy and the safety of ezetimibe (SCH 58235) co-administered with either atorvastatin or simvastatin in participants with homozygous familial hypercholesterolemia (FH).
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
This study's enrollment of 50 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Browse Hyperlipoproteinemia Type II studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
80 mg atorvastatin taken orally, once daily for 12 weeks
Drug: Atorvastatin · Drug: Placebo for Ezetimibe
10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
Drug: Atorvastatin · Drug: Ezetimibe
10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
Drug: Atorvastatin · Drug: Ezetimibe
80 mg simvastatin taken orally, once daily for 12 weeks
Drug: Simvastatin · Drug: Placebo for Ezetimibe
10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
Drug: Simvastatin · Drug: Ezetimibe
10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
Drug: Simvastatin · Drug: Ezetimibe
Tablets taken orally once daily in the morning
Tablets taken orally once daily in the morning or evening
Tablet taken orally once daily in the morning or evening
Tablets taken orally once daily in the morning or evening
Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C) measured directly
Time frame: Baseline and Up to Week 12
Percentage of participants with an Adverse Event (AE)
Time frame: Up to Week 12
Percent change from baseline in calculated LDL-C
Time frame: Baseline and Up to Week 12
Percent change from baseline in Total Cholesterol (TC)
Time frame: Baseline and Up to Week 12
Percent change from baseline in Triglycerides (TG)
Time frame: Baseline and Up to Week 12
Percent change from baseline in High-density-lipoprotein cholesterol (HDL-C)
Time frame: Baseline and Up to Week 12
Percent change from baseline in High-density-lipoprotein 2 cholesterol (HDL2-C)
Time frame: Baseline and Up to Week 12
Percent change from baseline in High-density-lipoprotein 3 cholesterol (HDL3-C)
Time frame: Baseline and Up to Week 12
Percent change from baseline in Apolipoprotein A-I (Apo A-I)
Time frame: Baseline and Up to Week 12
Percent change from baseline in Apolipoprotein B (Apo B)
Time frame: Baseline and Up to Week 12
Percent change from baseline in Lipoprotein(a) [Lp(a)]
Time frame: Baseline and Up to Week 12
No study locations are listed for this record.
Plan to share: No
Ran from May 2000 to primary completion in May 2001, 12 months.
Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 12 months is below that.
Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Atorvastatin · Simvastatin · Ezetimibe
Hyperlipoproteinemia Type II →